Dr. Sujitha Subash Padma Jeya was awarded with the PhD in Biotechnology from VIT University, Vellore, Tamil Nadu, India. In her PhD project she investigated the genetic variants associated with Schizophrenia, with special reference to gene polymorphisms in the Serotoninergic system, ESR1 and DNA repair gene (XRCC1) in Tamil population (South India). This study was supported by the Department of Biotechnology (DBT) Ministry of Science & Technology, Government of India. 

In 2018, Dr. Sujitha joined the Human Genetics Department, Precision Medicine Program, Sidra Medicine, Qatar, as a Research Specialist. Over there, she worked on several research projects funded by Qatar National Research Fund (QNRF). She was involved in validating the susceptible variants discovered through 'Whole Genome Sequencing in the Mendelian and Autism' disease subjects. But her special focus was finding the molecular biomarker for Diabetic retinopathy in Qatar's Population using multi-OMICS (circulating miRNA profiling, mRNA expression profiling, methylation profiling, proteomics profiling) approach. As part of the Diabetes Precision Medicine Program, she validated the hub of genes orchestrating the podocytes functions, which were discovered through the Geodata set analysis (retrospective analysis). She has demonstrated the involvement of susceptible transcription factors in pronephros development in Zebrafish hyperglycemic models. She also worked in the 'Qatar Genome Project' assessing the impact of amylase genes Copy Number Variation (Structural Variants) on adiposity in Qatar's Population.

Dr. Sujitha, joined Dr. Fares Al-Ejeh team as a Post-Doctoral Researcher in 2022, and is currently involved in finding clinically actionable potential biomarkers in Qatar's population for Cancer Precision Medicine.